E-SYNC T Cells

E-SYNC T Cells are an investigational autologous chimeric antigen receptor (CAR) T-cell therapy developed at the University of California, San Francisco (UCSF) for the treatment of glioblastoma. This therapy uses a patient's own T cells, which are genetically engineered using a lentiviral vector to express a synthetic Notch (synNotch) receptor that recognizes Epidermal growth factor receptor variant III (EGFRvIII)—a mutant protein found on some glioblastoma cells. Upon recognition of EGFRvIII, these primed T cells then induce expression of a CAR targeting either Ephrin type-A receptor 2 (EphA2) or Interleukin-13 receptor subunit alpha-2 (IL-13Rα2) antigens, both commonly expressed in glioblastoma. This two-step activation strategy is designed to enhance specificity and efficacy by ensuring robust immune responses against tumor cells while minimizing off-tumor toxicity. The approach has demonstrated superior persistence and efficacy compared to conventional CAR-T therapies in preclinical studies. The primary indication is for patients with EGFRvIII-positive glioblastoma[1][4][5].

Brand names

E-SYNC

Other names

E-SYNC CAR T cellssynNotch-CART cells